Kevzara’s approval was based on controlled trials, pharmacokinetic data in adults with rheumatoid arthritis, and pediatric-specific pharmacokinetic studies.
FDA Approves Regeneron and Sanofi’s Kevzara for Treatment of Patients with Active Polyarticular Juvenile Idiopathic Arthritis
Leave a comment
